October 24, 2025 12:00 ET | Source: Flare Therapeutics Inc. FX-909, the first small molecule targeting PPARG to be tested…
– QTX3034 monotherapy and the QTX3034-cetuximab combination demonstrated favorable safety profiles and clear clinical proof of concept, including confirmed responses…
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response…
October 19, 2025 10:00 ET | Source: AVACTA GROUP PLC Median progression free survival (PFS) has not been reached in…
October 19, 2025 08:00 ET | Source: RAPT Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) --…
October 14, 2025 08:05 ET | Source: Candel Therapeutics NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc.…
- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab…
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company…
SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing…
October 10, 2025 16:05 ET | Source: Vera Therapeutics BRISBANE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc.…